2016-10-01
CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent
Publication
Publication
Annals of Oncology , Volume 27 p. vi262
Additional Metadata | |
---|---|
doi.org/10.1093/annonc/mdw372.50, hdl.handle.net/1765/125589 | |
Annals of Oncology | |
Organisation | Erasmus MC: University Medical Center Rotterdam |
de Wit, R., Fizazi, K., Efstathiou, E., Dittamore, R. (R.), Hitier, S. (S.), Pantel, K., … de Bono, J. (2016). CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent. Annals of Oncology, 27. doi:10.1093/annonc/mdw372.50 |